Introduction
Cancer-targeted immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapies, bispecific antibodies, and checkpoint inhibitors, have made a profound impact on the treatment of oncology patients but may cause adverse…
Cancer-targeted immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapies, bispecific antibodies, and checkpoint inhibitors, have made a profound impact on the treatment of oncology patients but may cause adverse…